CURE

FDA Grants Breakthrough Designation to Sofi-cel for Relapsed/Refractory T-Cell ALL/LBL

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
CURE

Epkinly Improves Progression-Free Survival in Relapsed/Refractory DLBCL

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Targeted Oncology

Teclistamab Outperforms Standard of Care in Early Refractory Myeloma

Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
The American Journal of Managed Care

Patients With Penta-Refractory Myeloma May Benefit From BCMA-Directed Therapy

Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance. Patients with penta-relapsed refractory multiple myeloma (RRMM) exhibited ...

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

Initiation of phase 1 portion of the trial planned in 2H 2026-Phase 2 portion of the trial will initiate development of the elraglusib tablet in ...

Expert guidance urges caution before surgery for patients with treatment-resistant constipation

A new update from the American Gastroenterological Association (AGA) is calling for greater caution before surgery is considered for patients with refractory constipation, a severe, chronic form of ...